<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26069376</article-id>
      <article-id pub-id-type="pmc">4450564</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-47-332</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.157136</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Voriconazole-induced psychosis in a case of acute myeloid leukemia with febrile neutropenia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Hemendra</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kilara</surname>
            <given-names>Nalini</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Subramaniyan</surname>
            <given-names>Vyjayanthi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thyloth</surname>
            <given-names>Murali</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Psychiatry, M.S. Ramaiah Medical College, Bengaluru, Karnataka, India</aff>
      <aff id="aff2"><label>1</label>Department of Medical Oncology, M.S. Ramaiah Medical College, Bengaluru, Karnataka, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Hemendra Singh, E-mail: <email xlink:href="hemendradoc2010@gmail.com">hemendradoc2010@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>47</volume>
      <issue>3</issue>
      <fpage>332</fpage>
      <lpage>333</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>4</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Voriconazole-induced psychosis is a rare side effect. It is important that clinicians are made aware of voriconazole-induced potential psychosis. We report a case of voriconazole-induced psychosis that responded to haloperidol.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Haloperidol</kwd>
        <kwd>psychosis</kwd>
        <kwd>voriconazole</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>Introduction</title>
      <p>Voriconazole is a commonly prescribed antifungal drug, which is used for the treatment of invasive fungal infections as well as empirically for febrile neutropenic patients. The existing literature on voriconazole-induced hallucinations is based on previously published case reports.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] The findings of these reports suggest that the onset of voriconazole-induced hallucinations varies from 1-day to 1-week of initiation of voriconazole therapy and persists up to 5 days after stoppage of voriconazole.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] There is a paucity of literature on voriconazole-induced psychosis and its management. We report a case where a patient had voriconazole-induced psychosis, which responded to haloperidol.</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>A 57-year-old married male had a history of loss of appetite and melaena since 1-month. There was no past or family history of psychiatric or medical illness. On examination, the patient had bilateral cervical and axillary lymphadenopathy with pale oral cavity and dry mucosa. Peripheral blood smear showed acute leukemia with pancytopenia. Bone marrow and flow cytometry were done and the patient was diagnosed as a case of acute myeloid leukemia. Ultrasonography of the abdomen showed hepatomegaly. The patient's blood tests for HIV, syphilis, malaria, and hepatitis-B were negative. Computed tomography scan of the brain was normal. He was treated with induction chemotherapy with daunorubicin 90 mg/day for 3 days and cytarabine 150 mg/day for 7 days. The patient developed febrile neutropenia on day 7 of chemotherapy and was started on I.V. antibiotics: Imipenem and cilastatin combination, teicoplanin, and metronidazole along with I.V. voricanazole (400 mg twice a day). After 24 h of voriconazole therapy, the patient developed florid visual and second person derogatory auditory hallucinations, delusion of persecution, restlessness, and agitation without impairment of orientation and consciousness. Hence, voricanozole was stopped immediately and substituted with amphotericin B. The patient was treated with I.V. haloperidol 2.5 mg. However, whenever the patient was agitated, fearful, or unable to sleep, the dose of I.V. haloperidol was increased to a maximum of 10 mg/day. Thereby the patient's psychotic symptoms resolved within 2 days of initiating haloperidol. Hence, haloperidol was gradually tapered and then stopped within 2 days. After 15 days of completion of chemotherapy, the patient was afebrile and was no longer neutropenic.</p>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>There are certain observations that stand out in the present case, which need to be considered in our understanding of voriconazole-induced psychosis. Our case had developed psychosis after 1-day of voriconazole therapy for febrile neutropenia. The patient was treated with antibiotics, which were continued for 4 days even after the patient had recovered from psychosis. We did not find any connection between the hallucinations and other drugs administered to the patient. The dose of voriconazole that was administered was within the normal range. The biochemical parameters and neurological examinations also were normal at the time of psychotic symptoms. The patient continued to be febrile even after recovering from psychosis. The patient continued to have frank psychotic symptoms for 2 days even after voriconazole was stopped. Psychotic symptoms resolved within 2 days of initiating haloperidol therapy. According to Naranjo's Adverse Drug Reaction Probability Scale score for this adverse reaction was found to be 7, which showed that the adverse reaction was &#x201C;probable&#x201D; due to the drug.[<xref rid="ref3" ref-type="bibr">3</xref>]</p>
      <p>This also supports the transient course of voriconazole-induced psychotic symptoms, which have been described in previous reports.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] The existing literature on voriconazole-induced psychosis is almost entirely based on case reports. However, there is a paucity of literature about the management of such psychotic symptoms.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] There is a dearth of controlled studies to test the hypothesis that voriconazole-induced psychosis might have a pathophysiological basis (increased dopamine level) common with the other psychotic disorders, which respond well to antidopaminergic drugs such as haloperidol. There is a need for longitudinal controlled studies of voriconazole-induced psychotic disorder to test this hypothesis.</p>
    </sec>
    <sec sec-type="conclusion" id="sec1-4">
      <title>Conclusions</title>
      <p>Voriconazole-induced psychosis is not a common side-effect. It is important that clinicians are aware of the risk of voriconazole-induced psychosis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nill.</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> No.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrawal</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>LK</given-names>
            </name>
          </person-group>
          <article-title>Voriconazole-induced musical hallucinations</article-title>
          <source>Infection</source>
          <year>2004</year>
          <volume>32</volume>
          <fpage>293</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">15624894</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zonios</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Gea-Banacloche</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Childs</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Hallucinations during voriconazole therapy</article-title>
          <source>Clin Infect Dis</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>e7</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">18491963</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naranjo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Busto</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sandor</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A method for estimating the probability of adverse drug reactions</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1981</year>
          <volume>30</volume>
          <fpage>239</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">7249508</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Imhof</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schaer</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Schanz</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring</article-title>
          <source>Swiss Med Wkly</source>
          <year>2006</year>
          <volume>136</volume>
          <fpage>739</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">17183438</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyd</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Modi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Keevil</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Denning</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Adverse reactions to voriconazole</article-title>
          <source>Clin Infect Dis</source>
          <year>2004</year>
          <volume>39</volume>
          <fpage>1241</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">15486850</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
